Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Read the news release
Visit BioReference Health

Our Medicines

Turning Innovation into Impact by Delivering Next-Generation Therapies

OPKO Health has developed and brought to market innovative medicines that are available to patients around the world. By applying next‑generation science to proven technologies, our commercial therapies are designed to provide more effective and convenient treatment options for people with chronic diseases.

ngenla (somatrogon-ghla) injection

NGENLA® (somatrogon‑ghla) is a once‑weekly injection of a long-acting human growth hormone analog approved by the U.S. FDA for children aged 3+ who have growth failure due to insufficient natural growth hormone. Partnered with Pfizer and now approved in over 40 markets worldwide, NGENLA® is poised to transform the treatment landscape by offering a once-weekly regimen while delivering comparable growth outcomes to daily injections.

Learn More About NGENGLA
Rayaldee, calcifediol ER capsules

RAYALDEE®  is an extended‑release oral formulation of calcifediol, a vitamin D prohormone that the body converts into active vitamin D3. It is the first and only U.S. FDA‑approved medicine specifically indicated to raise serum 25D and lower intact parathyroid hormone in adults with secondary hyperparathyroidism and stage 3 or 4 chronic kidney disease with vitamin D insufficiency.

Learn More About Rayaldee